May 7th 2021
Post-treatment care for breast cancer survivors must be personalized to address each survivor’s unique experiences.
April 26th 2021
Apalutamide plus androgen deprivation therapy maintained an overall survival advantage over placebo for a broad population of patients with metastatic castration-sensitive prostate cancer after nearly 4 years of median follow-up.
April 23rd 2021
Sara A. Hurvitz, MD, can remember the exact moment she decided to become an oncologist. It was her first day at the University of Southern California School of Medicine, which she had entered in 1995 without a firm idea of what discipline she wanted to pursue.
April 11th 2021
Treatment with TAS-117, a highly potent and selective oral allosteric pan-v-akt murine thymoma viral oncogene homolog inhibitor, demonstrated some clinical efficacy in patients with ovarian cancer harboring PIK3CA E545K mutations and in those with breast cancer harboring PIK3CA H1047R and Akt1E17K mutations.
April 8th 2021
Encouraging efficacy data for ripretinib as a later-line therapy for patients with advanced gastrointestinal stromal tumor have investigators hypothesizing new approaches to derive even greater benefit with the agent.
March 27th 2021
Options for systemic treatment for patients with hepatocellular carcinoma have significantly expanded since 2017, when the sole available option was sorafenib. Now, the arsenal includes checkpoint inhibitors, targeted therapies, and combinations of both classes of drugs.
March 18th 2021
The coronavirus 2019 pandemic caused a 60% drop in the initiation of new clinical trials for anticancer therapies compared with prior years.
March 16th 2021
PARP inhibitors and novel combinations targeting the androgen receptor will help define the future treatment paradigm for patients with metastatic castration-resistant prostate cancer.
March 12th 2021
John L. Marshall, MD, has made it his mission to improve the lives of patients with GI cancers through innovative research, personalized medicine, and focused advocacy.